216 related articles for article (PubMed ID: 27911816)
1. Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology.
Han J; Jun Y; Kim SH; Hoang HH; Jung Y; Kim S; Kim J; Austin RH; Lee S; Park S
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14283-14288. PubMed ID: 27911816
[TBL] [Abstract][Full Text] [Related]
2. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.
Heibein AD; Guo B; Sprowl JA; Maclean DA; Parissenti AM
BMC Cancer; 2012 Aug; 12():381. PubMed ID: 22938713
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death.
Pourquier P; Montaudon D; Huet S; Larrue A; Clary A; Robert J
Biochem Pharmacol; 1998 Jun; 55(12):1963-71. PubMed ID: 9714316
[TBL] [Abstract][Full Text] [Related]
5. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
6. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.
Kadioglu O; Saeed MEM; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Life Sci; 2021 Nov; 284():119601. PubMed ID: 33991550
[TBL] [Abstract][Full Text] [Related]
8. Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2.
Hosokawa Y; Takahashi H; Inoue A; Kawabe Y; Funahashi Y; Kameda K; Sugimoto K; Yano H; Harada H; Kohno S; Ohue S; Ohnishi T; Tanaka J
Biochim Biophys Acta; 2015 Jun; 1850(6):1197-205. PubMed ID: 25644290
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.
Zhang S; Han L; Wei J; Shi Z; Pu P; Zhang J; Yuan X; Kang C
Int J Oncol; 2015 Apr; 46(4):1589-600. PubMed ID: 25625875
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
12. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Sarisozen C; Dhokai S; Tsikudo EG; Luther E; Rachman IM; Torchilin VP
Eur J Pharm Biopharm; 2016 Nov; 108():54-67. PubMed ID: 27569031
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
Motaln H; Koren A; Gruden K; Ramšak Ž; Schichor C; Lah TT
Oncotarget; 2015 Dec; 6(38):40998-1017. PubMed ID: 26517510
[TBL] [Abstract][Full Text] [Related]
16. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Bottero V; Busuttil V; Loubat A; Magné N; Fischel JL; Milano G; Peyron JF
Cancer Res; 2001 Nov; 61(21):7785-91. PubMed ID: 11691793
[TBL] [Abstract][Full Text] [Related]
17. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
18. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780.
Salvatore C; Camarda G; Maggi CA; Goso C; Manzini S; Binaschi M
Int J Oncol; 2005 Sep; 27(3):799-806. PubMed ID: 16077931
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
